You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Immune responses to pneumococcal polysaccharides at one month post-primary vaccination (primary ATP immunogenicity cohort): OPA

From: A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

  Clin group Com group
  N % ≥8 GMT N % ≥8 GMT
(95% CI) (95% CI) (95% CI) (95% CI)
Vaccine serotypes       
Serotype 1 209 88.5 128.9 210 90.0 122.1
(83.4 – 92.5) (102.7 – 161.7) (85.1 – 93.7) (98.3 – 151.7)
Serotype 4 207 100 698.3 207 98.1 609.3
(98.2 – 100) (619.6 – 786.9) (95.1 – 99.5) (519.6 – 714.3)
Serotype 5 207 98.6 127.9 210 96.7 98.6
(95.8 – 99.7) (109.0 – 149.9) (93.3 – 98.6) (83.0 – 117.1)
Serotype 6B 205 95.6 870.7 206 92.7 619.2
(91.8 – 98.0) (710.2 – 1067.6) (88.3 – 95.9) (483.4 – 793.2)
Serotype 7F 206 100 3905.8 208 100 3585.7
(98.2 – 100) (3420.2 – 4460.4) (98.2 – 100) (3119.8 – 4121.2)
Serotype 9V 207 100 1800.0 208 100 1851.3
(98.2 – 100) (1596.6 – 2029.3) (98.2 – 100) (1612.3 – 2125.8)
Serotype 14 209 99.5 1521.0 208 99.5 1485.8
(97.4 – 100) (1313.3 – 1761.6) (97.4 – 100) (1280.5 – 1724.0)
Serotype 18C 204 99.0 533.5 206 96.6 383.9
(96.5 – 99.9) (461.8 – 616.4) (93.1 – 98.6) (319.3 – 461.5)
Serotype 19F 206 98.1 689.6 206 97.1 573.5
(95.1 – 99.5) (581.1 – 818.2) (93.8 – 98.9) (477.2 – 689.3)
Serotype 23F 209 99.0 2716.7 207 99.5 2379.5
(96.6 – 99.9) (2316.3 – 3186.3) (97.3 – 100) (2043.4 – 2770.7)
Cross-reacting serotypes       
Serotype 6A 197 87.8 230.8 200 85.5 173.7
(82.4 – 92.0) (180.3 – 295.4) (79.8 – 90.1) (133.9 – 225.3)
Serotype 19A 197 42.1 18.1 199 37.7 15.1
(35.1 – 49.4) (13.7 – 23.8) (30.9 – 44.8) (11.5 – 19.8)
  1. ATP = according to protocol.
  2. OPA = opsonophagocytic activity.
  3. Clin = group of infants from Malaysia and Singapore who received the Phase III Clinical lot of PHiD-CV in the primary vaccination phase.
  4. Com = group of infants from Malaysia and Singapore who received the Commercial lot of PHiD-CV in the primary vaccination phase.
  5. N = number of infants with available results.
  6. 95% CI = 95% confidence interval.
  7. GMT = geometric mean titre.
  8. % = percentage of infants with antibody concentrations or OPA titres above the specified cut-off.